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Abstract
Endoscopic remission is the cornerstone of drug development and the guidance for daily clinical practice in Crohn's disease [CD]. However, although scoring systems for endoscopic activity in CD have been available for more than three decades, no consensus exists on the definition of endoscopic remission. In this viewpoint we describe the shortcomings of the current definition of endoscopic remission in ileocolonic CD and the essential requirements for a newly developed endoscopic scoring tool for endoscopic remission in CD.
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After the first description of Crohn's disease [CD] in 19321 it took more than 40 years before a successful ileocolonoscopy was performed.2 In the early 1980s, the superiority of endoscopy compared to barium X-ray studies was recognized.3,4 Endoscopy was still in its infancy, gastroenterologists struggled with technical issues and successful ileal intubation was rather rare.5 A first attempt to measure and classify endoscopic lesions and activity in CD was done in the European Cooperative Crohn's Disease Study.6 This resulted in a vague description of the different lesions without assessment of inter-observer agreement. In the late 1980s, the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif [GETAID] performed a prospective study to build an endoscopic score of severity in patients with CD using fibreoptic endoscopy.7 First, an inter-observer variation study was designed, each colonoscopy evaluation being performed simultaneously by a pair of endoscopists who did not communicate during the endoscopy. In a preparatory phase, the participating endoscopists had agreed on the items that should be assessed in the study. This led to a selection of nine items described literally and in a booklet with typical pictures to be displayed in each endoscopy room; three other items were discarded due to a lack of recognition agreement in spite of agreed definitions. The assessment of these nine items in five predefined segments from rectum to ileum, the evaluation of the affected and ulcerated surfaces per segment and the global evaluation of the severity on a linear analogue scale revealed good inter-endoscopist agreement, even if it was lower when the two endoscopists belonged to different centres.7 This proved that endoscopic data collected in a standardized manner were reproducible among well-trained endoscopists. Second, in parallel to this inter-observer variation study, the Crohn's disease endoscopic index of severity [CDEIS] was developed and validated on the same database.8 Based on a multiple linear regression model, the index was constructed by weighting segmental endoscopic lesions [deep and superficial ulcerations], segmental diseased and ulcerated surfaces, and observation at the endoscopy of ulcerated or non-ulcerated stenosis.8 This was a crucial step in drug development in CD. Collecting endoscopic data in a standardized manner allowed the endoscopic severity of disease to be assessed in an objective way in a patient before starting a treatment. Third, and still in parallel, a trial was undertaken to test if time-to-clinical relapse was delayed by a 5-week continuation of high-dose corticosteroids in patients in clinical but not endoscopic remission, after a standard 3- to 7-week corticosteroid treatment of a flare of CD.9 As CDEIS was not available at trial initiation, endoscopic remission was empirically defined as no active lesions, only scarred lesions, or minor lesions with at least a two-grade decrease on a six-grade scale and no deep ulceration. Surprisingly, the authors could not document any significant advantage of pursuing corticosteroid therapy as described above in terms of time-to-relapse. Consequently, clinical trials were developed primarily focusing on clinical disease activity and clinical remission.10 However, the use of the CDEIS in routine practice was found to be time consuming and complex to calculate and was therefore limited to clinical trials.11 To facilitate the uptake of the assessment of endoscopic lesions in CD, the Leuven group developed the Simplified Endoscopic Score for CD [SES-CD] through its correlation to the CDEIS.12 The SES-CD uses the same items as the CDEIS [ulcer, diseased surface, ulcerated surface and stenosis], but on an ordinal scale.
Endoscopic severity indices were thus appropriately developed, but there was no focus on endoscopic remission because this was not a target that could be reached with the available drugs at that time. Therefore, drug efficacy was essentially assessed through clinical scores, mainly based on clinical symptoms and some biological parameters. 
The advent of the biologics, in the first place infliximab, changed the treatment goals for CD tremendously.13 Over time and with the extension of therapeutic opportunities, evidence accumulated that mucosal healing [MH] defined as a regression or disappearance of endoscopic lesions in CD led to better outcomes in the long term.14-17 In a retrospective cohort study in patients with CD treated with infliximab, a significantly lower need for surgery was seen when complete [absence of ulcers that were present at baseline] or partial [residual ulcerations but clear endoscopic improvement] MH was achieved after a median of 6.7 months.15 In the long-term follow-up of the 'step up top down' trial a strict definition of MH was used. Patients who reached a SES-CD of zero 2 years after start of the trial were significantly more often in steroid-free remission at years 3 and 4 compared to those with an SES-CD of 1-9.14 Despite some evidence suggesting that MH was an achievable goal, it still took many years before MH was the primary endpoint in a clinical trial in CD.18 The EXTEND study evaluated the effect of adalimumab in active ileocolonic CD. The SES-CD was used as selection criterion for this trial. The primary endpoint was 'mucosal healing' defined as absence of mucosal ulceration at week 12, secondary end points were MH at week 52, and CDEIS remission defined as CDEIS ≤ 4 at weeks 12 and 52 and clinical outcome measures.18 In the MUSIC study evaluating certolizumab pegol in active ileocolonic CD, the primary outcome was mean change in CDEIS score at week 10; secondary outcome measures included endoscopic response [decrease in CDEIS score > 5 points], remission [CDEIS score < 6], complete remission [CDEIS score < 3] and mucosal healing [no ulcer] at weeks 10 and 54.19 These trials typically demonstrate the Babylonic confusion of tongues when talking about and assessing endoscopic remission in CD as completely different criteria were used independently to define the endpoint of endoscopic remission.
From our point of view three important issues must be highlighted.
First, we lack an objective, generally accepted definition of endoscopic remission. A high variation in the thresholds to define endoscopic remission is seen between different trials20,21 The work by the International Organization for the Study of Inflammatory Bowel Disease [IOIBD] describes extensively the various definitions used in the literature and proposed through a Delphi-like procedure what the authors considered the best available definitions of endoscopic response and remission.22 On top of that, empirically defined thresholds for endoscopic remission, using endoscopic indices of severity, are not relevant. For example, an extended ulcerated surface of 30% with superficial ulcerations and a diseased surface of 50% within one ileocolonic segment is considered by most endoscopists as active disease, but gives a CDEIS score below 3 [proposed to define a complete remission]. Although the IOIBD suggested defining endoscopic remission by an SES-CD of 0-2, sometimes other definitions are used to assess the treatment effect of a new therapeutic compound. The absence of a consensus on an appropriate definition of endoscopic response or remission may generate erroneous conclusions and mislead clinical research. Accordingly, the IOIBD emphasized that further research is warranted to better define endoscopic targets that can predict favourable long-term outcomes.22 Endoscopic remission is an extremity of the spectrum of endoscopic severity in CD. Current scoring systems only implement ulcerations [i.e. depth and extension], stenosis and surface affected by any lesions. The absence of further differentiation of other types of lesions hampers the scoring of endoscopic remission, because possibly other lesions are more important for the description of remission status.8,12 These shortcomings make the use of the current endoscopic scoring systems in a setting of endoscopic remission questionable.
Second, there is an ongoing debate on the role of central 'expert' reading and the value of the assessment of the local treating physician.23,24 Independent reading of endoscopic images leads to a better selection of eligible patients in clinical trials and impacts on the outcomes by reducing the placebo effect.25 When assessing endoscopic endpoints in clinical trials an independent central reading provides a better estimation of the treatment effect than the potentially biased local investigator. However, an endoscopic scoring system should also prove its value in daily clinical practice. Correct endoscopic scoring and assessment of endoscopic remission by the treating physician is also important for evaluation of the treatment effect and the planning of further treatment in daily practice. For this, the inter-observer variability of the score used should be limited, both for expert endoscopists and for community gastroenterologists. The reproducibility of the currently available scores used to determine CD endoscopic activity remains to be demonstrated for community endoscopists, even if the level of reproducibility was fair among expert endoscopists.26-29
Third, the relevance of endoscopic remission depends on the predictive value of the results of the scoring. Most of the data on the predictive value of endoscopic remission are based on different definitions of MH and endoscopic remission. The majority used absence of ulcers as the preferred definition.30 In a treat-to-target approach for CD the absence of ulcers is the most important target in addition to clinical remission.31,32 However, again a consensus on the definition of an ulcer is lacking. It is unclear whether a single ulcer or multiple ulcers in the same segment have the same prognosis. Complete disappearance of all endoscopic lesions is not necessarily needed.15 Further research is needed to define the threshold of endoscopic remission associated with a favourable outcome.

For these reasons, it is time for the construction of an objective, reproducible and scientifically relevant definition of endoscopic remission in CD. A new remission evaluation system based on an objective measure [depth and/or grade] is needed to overcome these shortcomings. We should aim for an assessment tool that gives a clear cut-off value of endoscopic remission that can be used in a clinical trial setting and daily clinical practice, and that is predictive for favourable outcomes over time. Several essential conditions need to be met to give a workable evaluation system. First, the system needs to be reproducible. It needs to produce identical or similar results when evaluating the same endoscopy by the same observer on different occasions or by different observers. Secondly, the remission evaluation system needs to be validated in a separate cohort. Third, the predictive value of the remission evaluation system needs to be tested in different settings to valorize the usefulness of the system in clinical practice and in clinical trials. When all these points are satisfied, it remains to be demonstrated in a randomized clinical trial that pursuing treatment to obtain this endoscopic remission is beneficial for the patient based on a specified endpoint.
We feel strongly that the construction of such a new evaluation system for endoscopic remission needs to start from scratch. It seems unwise to use the old definitions from past decades. Trying to remodel the CDEIS or SES-CD is not the solution. Treatments have changed, treatment goals have shifted and the endoscopic armamentarium has been improved impressively. Other endoscopic features such as scaring, changes in vascular pattern, appearance of pseudopolyps and loss of haustration are now recognized. In addition, the continuous disappearance of all endoscopic lesions is now achievable, which was still a Utopia 20 years ago.
Over the last two decades no prospective scientific efforts have been undertaken to tackle the issue of endoscopic remission in ileocolonic CD. We thus present a new project that might be a step in the right direction, but without any guarantee for a successful outcome. GETAID and Leuven University are developing such a new score or index of endoscopic remission in ileocolonic CD, through the CREDO programme [Crohn's disease endoscopic REmission: Definitions and Objectivation of endoscopic remission]. The CREDO programme consists of two parts. The first part, CREDO 1 [NCT03498625], is a cross-sectional study designed to objectively construct a reproducible measure of endoscopic remission in CD. The local investigator in 16 centres in Belgium and France will select 15 patients in clinical remission for more than 3 months with a recordable endoscopy [five in each degree of remission: complete, near complete or neither, according to his/her own appraisal]. The list of lesions to be recorded will be composed after a thorough discussion and a consensus meeting among 12 central readers. Videos will be allocated to central readers through a balanced incomplete block design, each central reader having to interpret 80 out of the 240 videos, allowing assessment of levels of inter-reader variation. Each central reader will provide identified lesions in seven pre-identified segments and global evaluation of remission depth on a linear analog scale and of remission grade on a give-grade ordinal scale. These lesions observed in the 960 readings will be used to construct an endoscopic remission tool that is highly correlated to remission depth or grade through mixed multiple regression modelling. The second part of the CREDO programme, CREDO 2 [NCT03487900], is a prospective observational longitudinal cohort study assessing the ability of the endoscopic remission tool measured in CD patients in clinical remission to predict sustained clinical remission during a 2-year follow-up. The primary endpoint is the absence of failure during the 2-year follow-up, failure being defined as CD flare, treatment escalation or disease complication at any time. In total, 320 patients in clinical remission for more than 3 months and whose treatment was not modified after the initial endoscopy will be included by the 16 local investigators, 20 within each centre, some of them previously included in CREDO 1. Each video will be read using the tool built in CREDO 1 by the local investigator, to check the applicability of this tool in routine practice, and by two central readers [and a third in case of disagreement between the latter] randomly selected among the 12 central readers. Each central reader and each local investigator will read 56 and 20 videos, respectively. Assuming a 20% annual failure rate and a 12% loss to follow-up, it will be possible by working on this sample of 320 patients to detect with a power of 80% an endoscopic remission level able to identify a group of high-risk patients in whom failure rate is increased by 20% as compared to the low-risk group. The CREDO programme should provide the first tool to specifically assess and define endoscopic remission in ileocolonic CD. Proof of the tool's clinical relevance can be made through its ability to accurately predict sustained clinical remission in ileocolonic CD in a setting of both central reading and daily clinical practice.
However, it must be taken into account that even with a well-developed scoring tool for endoscopic remission in CD, involvement of the small bowel proximal to the terminal ileum [Montreal classification L4] can impact on the prognosis of the course of further disease. Data on the prevalence of proximal involvement in patients with ileocolonic CD show a high variation.33,34 Furthermore, it is not clear which tool is best to assess small bowel involvement.35 For patients with proximal small bowel involvement, eventually a supplementary evaluation based on magnetic resonance enterography [MRE] and small bowel capsule endoscopy might be needed. 


In a subgroup of patients from the CREDO programme, a supplementary evaluation with MRE will be performed at baseline to correlate the findings from MRE in a subsequent step with the endoscopic remission score/index from CREDO, and the feasibility of a capsule endoscopy assessment is envisaged on this sub-group. Furthermore, biomarkers [faecal calprotectin, C-reactive protein] and histology will be obtained to assess their correlation with the CREDO score/ index. In a next step, forthcoming validation of the CREDO score/ index is needed in an independent cohort.
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